QNRX - Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product | Benzinga
ASHBURN, Va., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a specialty pharmaceutical company exclusively focused on the development and commercialization of innovative therapies that treat rare and orphan diseases, today announced it has filed U.S. and International patent applications for a novel combination product as a potential treatment of Netherton Syndrome.
This new product combines a broad spectrum serine protease inhibitor with an anti-inflammatory agent in a proprietary topical formulation. Quoin anticipates that patents arising from these applications will extend to at least 2044.
"As we continue to advance the clinical development of Quoin's lead asset for Netherton Syndrome, we are pursuing opportunities to strengthen our industry-leading position in this disease space. Today's announcement further underscores our commitment to innovation and to the expansion of our intellectual property portfolio. This novel product concept, formulated as a topical lotion, addresses the combined roles that serine protease inhibition and inflammation play in this disease," said Dr. Michael Myers, Chief Executive Officer of Quoin.
Quoin is currently enrolling patients in two clinical trials being conducted under its open Investigational New Drug (IND) application, evaluating its QRX003 topical lotion as a potential treatment of Netherton Syndrome. To date, Quoin remains the only company actively recruiting subjects into NS clinical trials that are being conducted under an open IND.
To find our more about Quoin's clinical studies, please visit